Deep vein thrombosis · participants at risk of venous thromboembolism
NMES showed no clear difference in total DVT compared with alternative prophylaxis (low certainty).
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
NMES may leads to higher total DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
NMES showed no clear difference in total DVT compared with dextran 40 (low certainty).
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
Combined NMES and low‐dose heparin may leads to lower total DVT compared with no prophylaxis (low certainty).
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
Combined NMES and low‐dose heparin may leads to lower total DVT compared with low‐dose heparin (low certainty).
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
NMES showed no clear difference in total DVT compared with GCS (low certainty).
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · participants at risk of venous thromboembolism
NMES probably leads to lower total DVT compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total DVT compared with LMWH (moderate certainty).
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
It is very uncertain whether fondaparinux changes total DVT compared with 1 mg warfarin (very low certainty).
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total DVT compared with placebo (moderate certainty).
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
1 finding from 1 review
Deep vein thrombosis · people requiring prevention of venous thromboembolism
Fondaparinux showed no clear difference in total DVT compared with mechanical thromboprophylaxis (low certainty).
1 finding from 1 review